Sandbox 77: Difference between revisions

Line 16:

==5-HT3 receptor antagonist: 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide)==

~~A 5HT3~~ antagonist shown to act as an antidepressant in diabetes-induced depression in mice; it resulted in a significant decrease in ~~5HT~~ in the midbrain after administration. <ref>Gupta D, Devadoss T, Mahesh R. ''A novel 5HT 3 antagonist 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.'' Behavioural brain research 297 (2016): 41-50. [http://www.sciencedirect.com/science/article/pii/S0166432815302217 DOI:10.1016/j.bbr.2015.10.007]</ref>

5-HT3 antagonists have a wide variety of uses such as treating nausea, vomiting, irritable bowel syndrome and mood disorders. Once a 5-HT3 antagonist has bound to a 5-HT3 receptor, serotonin binding is inhibited.<ref>Brunton, Laurence L.; Lazo, John S.; Parker, Keith L. (2006). Goddman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill. pp. 1000–3. ISBN 978-0-07-142280-2.</ref> 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) is a 5-HT3 antagonist shown to act as an antidepressant in diabetes-induced depression in mice; it resulted in a significant decrease in 5-HT in the midbrain after administration. <ref>Gupta D, Devadoss T, Mahesh R. ''A novel 5HT 3 antagonist 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.'' Behavioural brain research 297 (2016): 41-50. [http://www.sciencedirect.com/science/article/pii/S0166432815302217 DOI:10.1016/j.bbr.2015.10.007]</ref>

==References==

Sandbox 77: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 16: / Line 16: @@
 ==5-HT3 receptor antagonist: 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide)==
-A 5HT3 antagonist shown to act as an antidepressant in diabetes-induced depression in mice; it resulted in a significant decrease in 5HT in the midbrain after administration. <ref>Gupta D, Devadoss T, Mahesh R. ''A novel 5HT 3 antagonist 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.'' Behavioural brain research 297 (2016): 41-50. [http://www.sciencedirect.com/science/article/pii/S0166432815302217 DOI:10.1016/j.bbr.2015.10.007]</ref>
+-HT3 antagonists have a wide variety of uses such as treating nausea, vomiting, irritable bowel syndrome and mood disorders. Once a 5-HT3 antagonist has bound to a 5-HT3 receptor, serotonin binding is inhibited.<ref>Brunton, Laurence L.; Lazo, John S.; Parker, Keith L. (2006). Goddman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill. pp. 1000–3. ISBN 978-0-07-142280-2.</ref> 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) is a 5-HT3 antagonist shown to act as an antidepressant in diabetes-induced depression in mice; it resulted in a significant decrease in 5-HT in the midbrain after administration. <ref>Gupta D, Devadoss T, Mahesh R. ''A novel 5HT 3 antagonist 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.'' Behavioural brain research 297 (2016): 41-50. [http://www.sciencedirect.com/science/article/pii/S0166432815302217 DOI:10.1016/j.bbr.2015.10.007]</ref>
 ==References==